The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat.
Chemokines have well characterized proinflammatory actions, including the ability to induce extravasation of leukocytes that participate in chronic inflammation. In this study, we evaluated the role of a C-C chemokine, RANTES, in the chronic phase of a rat model of colitis. Colitis was induced by intracolonic administration of trinitrobenzene sulfonic acid. At various timepoints thereafter (2 h to 14 days), colonic tissue levels of several chemokines were measured. Unlike the expression of monocyte chemoattractant protein-1, macrophage inflammatory protein-2, and cytokine-induced neutrophil chemoattractant, the expression of RANTES was significantly elevated during the chronic phase of colitis (> or =7 days after induction). Colonic RANTES mRNA expression was also significantly elevated during the chronic phase of colitis. The numbers of macrophages and monocytes in the colonic mucosa increased substantially during the chronic phase, as did expression of two of the receptors (CCR1 and CCR5) to which RANTES is known to bind. Administration on days 7 through 14 after trinitrobenzene sulfonic acid administration of a CCR1/CCR5 receptor antagonist, Met-RANTES, resulted in a significant reduction of both macroscopic and microscopic colonic damage, as well as reducing the recruitment into the colon of monocytes, mast cells, and neutrophils. In some rats, treatment with Met-RANTES resulted in a near-complete resolution of colonic damage and inflammation. These results suggest a crucial role of RANTES in the progression from acute to chronic inflammation in a rat model of colitis.
Ajuebor
M N
MN
Mucosal Inflammation Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
Hogaboam
C M
CM
Kunkel
S L
SL
Proudfoot
A E
AE
Wallace
J L
JL
D000208:Acute Disease; D000285:Administration, Rectal; D000818:Animals; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology; D018946:Chemokine CCL5 / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000096:biosynthesis / Q000494:pharmacology / Q000502:physiology*; D002908:Chronic Disease; D003092:Colitis / Q000209:etiology / Q000276:immunology* / Q000473:pathology* / Q000517:prevention & control; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D006241:Haptens / Q000008:administration & dosage; D018836:Inflammation Mediators / Q000008:administration & dosage / Q000502:physiology*; D007275:Injections, Intravenous; D007958:Leukocyte Count; D008297:Male; D008407:Mast Cells / Q000276:immunology / Q000473:pathology; D009000:Monocytes / Q000276:immunology / Q000473:pathology; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar; D054389:Receptors, CCR1; D019713:Receptors, CCR5 / Q000096:biosynthesis / Q000235:genetics; D019707:Receptors, Chemokine / Q000096:biosynthesis / Q000235:genetics; D013997:Time Factors; D014302:Trinitrobenzenesulfonic Acid / Q000008:administration & dosage / Q000276:immunology
C515302:Ccr1 protein, rat; D018946:Chemokine CCL5; D006241:Haptens; D018836:Inflammation Mediators; C108335:RANTES, Met-; D012333:RNA, Messenger; D054389:Receptors, CCR1; D019713:Receptors, CCR5; D019707:Receptors, Chemokine; D014302:Trinitrobenzenesulfonic Acid